

Early versus delayed cranioplasty after decompressive craniectomy in traumatic brain injury: a multicenter observational study within CENTER-TBI and Net-QuRe

Rick J. G. Vreeburg, MD,¹ Ranjit D. Singh, MD,¹ Inge A. M. van Erp, MD,¹ Tommi K. Korhonen, MD, PhD,^{2,3} John K. Yue, MD,⁴ Harry Mee,² Ivan Timofeev, MD, PhD,² Angelos Kolias, MD, PhD,² Adel Helmy, MBBChir, PhD,² Bart Depreitere, MD, PhD,⁵ Wouter A. Moojen, MD, PhD,¹ Alexander Younsi, MD, PhD,⁶ Peter Hutchinson, MD, PhD,² Geoffrey T. Manley, MD, PhD,⁴ Ewout W. Steyerberg, PhD,⁷ Godard C. W. de Ruiter, MD, PhD,¹ Andrew I. R. Maas, MD, PhD,^{8,9} Wilco C. Peul, MD, PhD,¹ Jeroen T. J. M. van Dijck, MD, PhD,¹ Hugo F. den Boogert, MD,¹ Jussi P. Posti, MD, PhD,¹⁰ and Thomas A. van Essen, MD, PhD, MSc,^{1,11} for the CENTER-TBI Participants and Investigators

¹University Neurosurgical Center Holland, Leiden University Medical Center, Haaglanden Medical Center and Haga Teaching Hospital, Leiden and The Hague, The Netherlands; ²Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge and Addenbrooke's Hospital, Cambridge, United Kingdom; ³Neurocenter, Department of Neurosurgery and Research Unit of Clinical Neuroscience, Neurosurgery, Oulu University Hospital and University of Oulu, Finland; ⁴Department of Neurosurgery, University of California, San Francisco, California; ⁵Department of Neurosurgery, University Hospital Leuven, Belgium; ⁶Department of Neurosurgery, University Hospital Heidelberg, Germany; ⁷Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; ⁸Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium; ⁹Department of Translational Neuroscience, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium; ¹⁰Neurocenter, Department of Neurosurgery and Turku Brain Injury Center, Turku University Hospital and University of Turku, Finland; and ¹¹Department of Surgery, Division of Neurosurgery, QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada

OBJECTIVE The aim of this study was to compare the outcomes of early (≤ 90 days) and delayed (> 90 days) cranioplasty following decompressive craniectomy (DC) in patients with traumatic brain injury (TBI).

METHODS The authors analyzed participants enrolled in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) and the Neurotraumatology Quality Registry (Net-QuRe) studies who were diagnosed with TBI and underwent DC and subsequent cranioplasty. These prospective, multicenter, observational cohort studies included 5091 patients enrolled from 2014 to 2020. The effect of cranioplasty timing on functional outcome was evaluated with multivariable ordinal regression and with propensity score matching (PSM) in a sensitivity analysis of functional outcome (Glasgow Outcome Scale–Extended [GOSE] score) and quality of life (Quality of Life After Brain Injury [QOLIBRI] instrument) at 12 months following DC.

RESULTS Among 173 eligible patients, 73 (42%) underwent early cranioplasty and 100 (58%) underwent delayed cranioplasty. In the ordinal logistic regression and PSM, similar 12-month GOSE scores were found between the two groups (adjusted odds ratio [aOR] 0.87, 95% CI 0.61–1.21 and 0.88, 95% CI 0.48–1.65, respectively). In the ordinal logistic regression, early cranioplasty was associated with a higher risk for hydrocephalus than that with delayed cranioplasty (aOR 4.0, 95% CI 1.2–16). Postdischarge seizure rates (early cranioplasty: aOR 1.73, 95% CI 0.7–4.7) and QOLIBRI scores (β –1.9, 95% CI –9.1 to 9.6) were similar between the two groups.

CONCLUSIONS Functional outcome and quality of life were similar between early and delayed cranioplasty in patients who had undergone DC for TBI. Neurosurgeons may consider performing cranioplasty during the index admission (early)

ABBREVIATIONS aOR = adjusted odds ratio; DC = decompressive craniectomy; CENTER-TBI = Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; ECI = extracranial intervention; GCS = Glasgow Coma Scale; GOSE = Glasgow Outcome Scale–Extended; ICP = intracranial pressure; IMPACT = International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury; IQR = interquartile range; Net-QuRe = Neurotraumatology Quality Registry; PSM = propensity score matching; QOL = quality of life; QOLIBRI = Quality of Life after Brain Injury; RCT = randomized controlled trial; TBI = traumatic brain injury.

SUBMITTED September 20, 2023. **ACCEPTED** January 26, 2024.

INCLUDE WHEN CITING Published online April 26, 2024; DOI: 10.3171/2024.1.JNS232172.

to simplify the patient's chain of care and prevent readmission for cranioplasty but should be vigilant for an increased possibility of hydrocephalus.

Clinical trial registration nos.: CENTER-TBI, NCT02210221 (clinicaltrials.gov); Net-QuRe, NTR6003 (trialsearch.who.int) and NL5761 (onderzoekmetmensen.nl)

<https://thejns.org/doi/abs/10.3171/2024.1.JNS232172>

KEYWORDS cranioplasty; traumatic brain injury; timing; complication; early; delayed; trauma

EACH year in Europe, severe traumatic brain injury (TBI) causes an estimated 82,000 deaths with current trends indicating consistent annual increases despite widespread efforts and awareness to combat this “silent epidemic.”^{1–3} An important complication of severe TBI is increased intracranial pressure (ICP) due to severe brain swelling posttrauma or the mass effect arising from the primary lesion. Decompressive craniectomy (DC) is the treatment of last resort for medically refractory ICP and can be performed as part of a primary procedure (after immediate evacuation of a mass lesion) or as a secondary procedure (to treat medically refractory ICP elevation).⁴ As a secondary treatment, it allows immediate outward expansion of brain tissue, lowers ICP, and consequently improves cerebral blood flow.^{5–10} The surgical approach is usually a hemicraniectomy but can be a bifrontal craniectomy.¹¹

After a DC, neurosurgeons must determine when to reconstruct the bone defect by cranioplasty. There are no widely accepted guidelines to facilitate this decision, although the timing of cranioplasty has been abundantly discussed in the literature.^{12–19} In general, a pragmatic approach is employed; once the brain is sufficiently sunken, the skull is rebuilt. Cranioplasty is associated with high rates (10%–40%) of complication, including postoperative infection, bone resorption, hydrocephalus, and seizures.^{20,21} Some studies have suggested a benefit if cranioplasty is performed within 90 days after DC to potentially reverse cognitive, language, and motor deficits, referred to as “syndrome of the trephined,”²² as delayed reconstruction can impact the type and intensity of rehabilitation services.^{12,13} Conversely, early cranioplasty has been associated with higher risks for hydrocephalus and surgical site infection,¹⁴ and not all patients are sufficiently stable to undergo the procedure in this period. A recent consensus statement on post-TBI cranioplasty recommended further prospective research on the timing of cranioplasty and subsequent neurological outcomes.²³ We aimed to determine the comparative effectiveness of early versus delayed cranioplasty after DC in TBI patients. In keeping with the artificial nature of the 90-day (3-month) cutoff, we also assessed different predefined cutoffs, namely ultra early (< 6 weeks), early (6 weeks–3 months), intermediate (3–6 months), and late (> 6 months).

Methods

Study Design and Population

This observational cohort study used data obtained from two prospective, multicenter, observational cohorts: the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) and the Neurotraumatology Quality Registry (Net-QuRe)

studies.²⁴ CENTER-TBI is registered with ClinicalTrials.gov (registration no. NCT02210221). Net-QuRe is registered with the International Clinical Trials Registry (registration no. NTR6003, trialsearch.who.int) and the Dutch National Trial Register (registration no. NL5761, onderzoekmetmensen.nl). These parent studies were conducted in accordance with Good Clinical Practice (CPMP/ICH/135/95). The current study was predefined in a protocol.²⁵ Participants in CENTER-TBI were enrolled between 2014 and 2017 from 65 centers across Europe and Israel. Participants in Net-QuRe were enrolled between 2015 and 2020 from 8 centers in the Netherlands. The study follows the Strengthening the Reporting of Observational Studies in Epidemiology statement and corresponds to stage 3 in the IDEAL framework (Idea, Development, Exploration, Assessment, and Long-term study).²⁶ The study was planned to use the convenience sample provided by the CENTER-TBI.

Inclusion criteria for the current study were adults with TBI who had undergone DC and subsequent cranioplasty. Patients were excluded if they met any of the following conditions: 1) missing time intervals between DC and cranioplasty, and 2) missing Glasgow Outcome Scale–Extended (GOSE) score data.

Interventions

Initial surgical treatment consisted of primary or secondary DC to decrease ICP. The DC did or did not include evacuation of a hematoma using a bifrontal craniectomy or hemicraniectomy approach. To restore the bone defect, a cranioplasty was performed as a secondary intervention. The timing of the cranioplasty and the materials used followed the treating neurosurgeon's preference, inherent to the observational nature of the study. Both autologous bone grafts and synthetic grafts were used to repair the cranial defect. Cranioplasty performed ≤ 90 days after DC was classified as early, and cranioplasty performed > 90 days after DC was classified as delayed, per the most widely accepted and published definition of early and delayed cranioplasty^{12–19,27,28} and the definition used in the recent post-TBI cranioplasty consensus statement.²³ However, considering the relatively arbitrary nature of this stratification, we also performed sensitivity analyses with different thresholds.

Outcomes

The primary outcome was the GOSE score at 12 months. The GOSE is an internationally used measure for functional outcome and consists of an 8-point scale ranging from 1 (death) to 8 (upper good recovery).²⁹ The GOSE was applied mainly by interviews and was sometimes complemented with postal or web-based questionnaires.

Secondary outcomes were quality of life (QOL), as measured by the Quality of Life after Brain Injury (QOLIBRI) instrument at 12 months postinjury; occurrence of hydrocephalus (defined as the radiological appearance of enlarged ventricles or surgery to manage hydrocephalus); and post-TBI seizure at the 3-, 6-, and 12-month follow-ups and noted as having “occurred from TBI up until this follow-up time point.”³⁰ Hydrocephalus and seizures were defined as binary variables (occurred vs did not occur).

Statistical Analysis

Baseline patient characteristics are reported using standardized mean differences between the early and delayed cranioplasty groups. We used model specifications as in the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) models for the probability of death and an unfavorable outcome (in percentages) to correct for the severity of the initial injury. The IMPACT model has been extensively validated for TBI.^{31–33} Random-effects proportional odds ordinal regression was used for the primary outcome (GOSE score). Age, baseline Glasgow Coma Scale (GCS) score, baseline pupil reactivity, and admission head CT findings (midline shift, acute subdural hematoma, epidural hematoma, and intracerebral hematoma) were considered confounders and were included as independent variables. Data on CT imaging variables were collected using the primary CT scan (per protocol, done within 24 hours of admission). Results of the regression yielded estimations for adjusted odds ratios (aORs) and 95% confidence intervals. The odds ratios regarding the GOSE score indicate the odds per 1-point increase on the GOSE, where early surgery was compared with delayed. Secondary outcomes were analyzed with random-effects logistic (hydrocephalus and seizures) and linear (QOLIBRI) regression.

To quantify and compare the between-center differences in early cranioplasty, we calculated the median odds ratio, which quantifies treatment variation between centers that is not attributable to chance and not explained by other (case-mix) factors. The effect of this intercenter variance of early cranioplasty on primary outcome was analyzed using an instrumental variable analysis. This analysis compared centers based on their various preferences for performing early cranioplasty, as measured by the case-mix–adjusted probability of undergoing early cranioplasty at each participating center.

Additional analyses of the GOSE score, hydrocephalus, and seizure occurrence were performed using the timing between DC and cranioplasty as a continuous variable rather than a binary one (early vs delayed). These odds ratios are expressed as per interquartile range (IQR) increase. Also, ultra-early cranioplasty (within 42 days, i.e., < 6 weeks) was compared to cranioplasty at or after 42 days. Exploratory subgroup analyses for the primary outcome were performed in 10 subgroups: age < 50 years, age ≥ 50 years, baseline GCS score < 9 (severe TBI), baseline GCS score ≥ 9 (moderate/mild TBI), location of DC (bifrontal craniectomy/hemicraniectomy), type of DC (primary/secondary), and whether any major extracranial intervention (ECI) was performed during the initial admission (yes/no). A major ECI was defined as any ECI that

required hospitalization on its own (e.g., external fixation of a limb, damage control thoracotomy, damage control laparotomy, extraperitoneal pelvic packing, craniomaxillofacial reconstruction, tracheostomy, vertebrae fixation, and debridement of penetrating injuries). Undergoing a major ECI can interfere with the normal rehabilitation process and was therefore included as a subgroup. Primary DC was defined as initial surgical evacuation of a lesion within 24 hours of TBI. Secondary DC was defined as a preemptive approach to the treatment of suspected ICP or as a last-resort treatment for refractory ICP.

We performed a supplementary subgroup analysis, dividing the participating centers into three subgroups based on cranioplasty preference: preferring early cranioplasty, preferring delayed cranioplasty, and no clear preference. The three subgroups were based on the coefficients from a similar logistic regression model containing the same independent variables as the primary analysis.

Further sensitivity analyses were performed using propensity score matching (PSM). We aimed for balanced parallel groups (1:1) using a nearest-neighbor approach with a caliper of 0.16. Thus, participants who had undergone early cranioplasty were only matched to delayed cranioplasty patients if the maximum difference between propensity scores was < 0.16. Additionally, a similar sensitivity analysis was performed using the median timing between DC and cranioplasty, in days, as a cutoff to create two groups. These PSM models contained the same independent variables as the primary ordinal regression model.

Last, a supplementary sensitivity analysis was done using intensive care discharge variables (neuroworsening, time to obey commands [days], ventilation duration [days], and GCS score) and hospital length of stay (days) as confounders.

Statistical analysis was performed using R version 4.0.3 (The R Foundation for Statistical Computing). Missing data were imputed using the mice package. Data were accessed with a bespoke data management tool, Neurobot (research resource identifier: SCR_01700).

Results

The CENTER-TBI cohort consisted of 4509 participants and the Net-QuRe cohort of 937 (355 patients were included in both studies). These cohorts combined yielded 363 unique patients who had undergone DC for intractable ICP after TBI, 97 of whom died before undergoing cranioplasty. For 39 participants, it was unknown whether a cranioplasty was performed within the follow-up period. The remaining 227 participants underwent subsequent cranioplasty, and 54 were excluded because the time between DC and cranioplasty was unknown (n = 48) or a GOSE score was missing (n = 6). Accordingly, 173 patients were available for primary and secondary outcome analyses. Of those, 73 underwent early cranioplasty and 100 delayed cranioplasty (Fig. 1). The median time between DC and cranioplasty between the groups was 101 days (IQR 42–116 days; Supplemental Fig. 1). The median time in the early group was 36 days; in the delayed group, 116 days.

The two cranioplasty groups were comparable in terms




FIG. 1. Flow diagram of study population and data analysis. ‡532 patients were included in both studies, *primary outcome, §secondary outcome. Figure is available in color online only.

of age, sex, time between injury and DC, median GCS score (overall and motor), American Society of Anesthesiologists physical classification status, DC location, and presence of head CT variables (Table 1). IMPACT scores (core model for death and unfavorable outcome, respectively) provided a summary measure for baseline prognosis and were similar for the two groups (median 35, IQR 25–58 vs 33, IQR 22–55; median 57, IQR 39–73 vs 52, IQR 36–68, respectively). Patients in the early cranioplasty group were hospitalized longer than those in the delayed group (median 37 days, IQR 19–65 days vs 25 days, IQR 10–51 days), though the difference between the two was not statistically significant. Baseline characteristics were similar between the propensity score–matched groups (63 in both groups; Supplemental Table 1).

The proportional distribution of GOSE scores showed no consistent shift in functional outcome by either early or delayed cranioplasty (Fig. 2). The median QOLIBRI scores were 68 (IQR 56–75) and 64 (IQR 53–74) in the early and delayed cranioplasty groups, respectively. Following cranioplasty, 13 cases of hydrocephalus were reported, 9 (12%) in the early group and 4 (4%) in the de-

layed group. Seizures were reported in 20 participants, 11 (15%) in the early and 9 (9%) in the delayed cranioplasty groups. Importantly, the occurrence of seizures was sometimes only noted as having “occurred from TBI up until this follow-up time point” without an actual occurrence date (before or after some cranioplasty dates). A total of 7 patients died between cranioplasty and the 12-month follow-up, 4 (5%) in the early group and 3 (3%) in the delayed group.

The ordinal logistic regression model showed no statistically significant difference in 12-month GOSE scores between early and delayed cranioplasty groups (aOR 0.87, 95% CI 0.61–1.21). Similarly, no statistically significant difference was found in 3- and 6-month GOSE scores (aOR 0.95, 95% CI 0.6–1.2 and aOR 1, 95% CI 0.6–1.9, respectively; Supplemental Table 2).

Early cranioplasty was associated with a higher incidence of hydrocephalus (aOR 4, 95% CI 1.2–16; Table 2). No statistical difference was found in postdischarge seizure occurrence between the two groups, but the point estimate suggested a higher seizure risk for early cranioplasty (aOR 1.7, 95% CI 0.67–4.7).

TABLE 1. Baseline and treatment characteristics of study population

Variable	Early	Delayed	Standardized Mean Difference	p Value	Missing Data (%)
No. of patients	73	100			
Age in yrs	44 (29, 58)	44 (24, 56)	0.09	0.52	0
Male sex	51 (70)	72 (72)	0.05	0.89	0
GCS score	6 (3, 10)	7 (4, 14)	0.25	0.12	20 (12)
GCS motor score	3 (1, 5)	4 (1, 6)	0.16	0.24	5 (3)
Severity of TBI			0.29	0.34	12 (7)
Mild, GCS score 13–15	11 (16)	27 (29)			
Mod, GCS score 9–12	10 (15)	11 (12)			
Severe, GCS score <9	46 (69)	56 (60)			
Pupils			0.22	0.37	10 (6)
Both reacting	51 (73)	76 (82)			
One reacting	8 (11)	6 (6)			
Both unreactive	11 (16)	11 (12)			
ASA status			0.16	0.80	4 (2)
I, healthy	43 (60)	58 (60)			
II, mild systemic illness	19 (26)	28 (29)			
III, severe systemic illness	8 (11)	7 (7)			
IV, severe systemic illness that is constant threat to life	2 (3)	4 (4)			
Cause of injury			0.51	0.11	4 (2)
Road traffic incident	22 (31)	36 (37)			
Incident fall	26 (37)	42 (43)			
Other nonintentional	7 (10)	5 (5)			
Violence or assault	9 (13)	3 (3)			
Act of mass violence	2 (3)	1 (1)			
Suicide attempt	4 (6)	5 (5)			
Unknown	1 (1)	6 (6)			
Major ECI*	19 (26)	31 (31)	0.11	0.59	0
Epidural hematoma	20 (29)	20 (22)	0.18	0.52	13 (8)
SDH, acute	47 (68)	54 (59)	0.22	0.39	13 (8)
SDH, subacute/chronic	6 (9)	3 (3)	0.24	0.30	13 (8)
Cerebral contusion	46 (67)	61 (67)	0.07	0.92	13 (8)
Traumatic SAH	53 (77)	64 (70)	0.20	0.47	13 (8)
Skull fracture	41 (68)	55 (66)	0.11	0.81	26 (15)
Midline shift†	34 (68)	39 (43)	0.16	0.61	13 (8)
Compressed basal cisterns	36 (52)	48 (53)	0.06	0.92	13 (8)
Diffuse axonal injury	5 (29)	6 (46)	0.35	0.58	143 (83)
IMPACT unfavorable outcome score‡	57 (39, 73)	52 (36, 68)	0.12	0.49	
IMPACT death score‡	35 (25, 58)	33 (22, 55)	0.14	0.43	
DC location			0.35	0.46	83 (48)
Bifrontal craniectomy	6 (14)	9 (19)			
Lt hemicraniectomy	14 (33)	17 (36)			
Rt hemicraniectomy	23 (53)	21 (45)			
Time btwn injury & DC in days	1 (0, 1)	1 (0, 1)	0.13	0.92	75 (43)
DC reason			0.55	0.22	69 (40)
Preemptive approach for raised ICP	11 (22)	13 (24)			
Raised ICP (last resort)	14 (29)	19 (35)			
CT evidence of raised ICP	12 (24)	11 (20)			

CONTINUED ON PAGE 900 »

» CONTINUED FROM PAGE 899

TABLE 1. Baseline and treatment characteristics of study population

Variable	Early	Delayed	Standardized Mean Difference	p Value	Missing Data (%)
DC reason (<i>continued</i>)					
Not planned but decided due to intraop brain swelling	12 (24)	7 (13)			
Routinely performed w/ acute SDH or contusion evacuation	0 (0)	4 (7)			
Development of cerebral infarction	0 (0)	1 (2)			
DC type			0.61	0.06	81 (47)
Isolated procedure	12 (28)	9 (18)			
Association w/ acute SDH removal	27 (63)	24 (49)			
Association w/ contusion/ICH removal	1 (2)	6 (12)			
Association w/ acute SDH & contusion/ICH removal	3 (7)	10 (20)			
Hospital length of stay	37 (19, 65)	25 (10, 51)	0.34	0.34	9 (5)

ASA = American Society of Anesthesiologists; ICH = intracranial hemorrhage; Mod = moderate; SAH = subarachnoid hemorrhage; SDH = subdural hematoma.

Values are expressed as the median (IQR) or number (%), unless indicated otherwise.

* An ECI requiring a hospital admission/intervention on its own, for example, external fixation of a limb, damage control thoracotomy, etc.

† Defined as midline shift more than 5 mm.

‡ Scores give the probability of an unfavorable outcome or death at 6 months postinjury.

When using cranioplasty timing as a continuous variable, timing was not associated with differences in the GOSE score (aOR 1.1 for IQR increase of 74 days, 95% CI 0.88–1.3) or seizure occurrence (aOR 0.86, 95% CI 0.49–1.4), but a shorter time to cranioplasty was associated with a higher risk for hydrocephalus (aOR 2.5, 95% CI 1.1–7.1; Supplemental Table 3 and Supplemental Fig. 2).

There was no difference in QOLIBRI scores comparing the early and delayed cranioplasty groups (Table 2). Unadjusted analyses of early cranioplasty to all outcomes yielded comparable associations to the adjusted analyses. In a sensitivity analysis using PSM, incorporating baseline variables yielded an aOR for GOSE score of 0.88 (95% CI 0.48–1.65). Moreover, when using intensive care dis-




FIG. 2. Proportional distribution of GOSE scores between early and delayed cranioplasty groups. Figure is available in color online only.

TABLE 2. Associations of early cranioplasty with 12-month outcomes

Outcome	Early (n = 73)	Delayed (n = 100)	Effect Estimate	Unadjusted (95% CI)	Adjusted (95% CI)
GOSE score	4 (2, 5)	4 (2, 6)	OR	0.76 (0.56–1.1)	0.87 (0.61–1.21)
Hydrocephalus	9 (12)	4 (4)	OR	3.4 (1.1–13)	4 (1.2–16)
Seizures	11 (15)	9 (9)	OR	1.8 (0.7–4.7)	1.73 (0.67–4.7)
QOLIBRI	68 (56, 75)	64 (53, 74)	β	–1.9 (–10 to 14)	0.21 (–9.1 to 9.6)

Values are expressed as median (IQR) or number (%), unless indicated otherwise.

charge variables and length of stay, the aOR was 1.1 (95% CI 0.77–1.5; Supplemental Table 4). In PSM using the median timing as a cutoff point (101 days), the aOR for GOSE score was 1.1 (95% CI 0.79–1.6); for hydrocephalus, 4.8 (95% CI 1.1–34); and for seizure, 1.5 (95% CI 0.49–4.9; Supplemental Table 3).

The median ORs were 2.3 and 2.1 for intercenter and intercountry random-effects variance, respectively (Supplemental Fig. 3), meaning that there is a 2 times greater probability of undergoing early cranioplasty for an identical patient in one center versus another random center or country. In an instrumental variable analysis, there were no evident disparities in treatment effect between the participating centers (aOR 0.96, 95% CI 0.86–1.1).

In a subgroup analysis, no difference in the GOSE score was found between early or delayed cranioplasty in patients with an age < 50 years or $\geq$ 50 years (n = 107, aOR 0.84, 95% CI 0.58–1.2; n = 66, aOR 1, 95% CI 0.7–1.5, respectively). Furthermore, cranioplasty timing did not result in a difference in GOSE scores when comparing participants with a GCS score < 9 or $\geq$ 9 (n = 105, aOR 0.96, 95% CI 0.64–1.3; n = 68, aOR 1.1, 95% CI 0.72–1.6, respectively). Cranioplasty performed ultra early (e.g., within 42 days, < 6 weeks) was also not associated with differences in the GOSE score (aOR 0.82, 95% CI 0.41–2.6). When comparing early to delayed cranioplasty in patients who had undergone a major ECI during the initial admission, early cranioplasty was associated with an improved functional outcome (n = 50, aOR 1.9, 95% CI 1.3–2.7). In those who did not undergo a major ECI, early cranioplasty was negatively associated with the GOSE score (n = 123, aOR 0.63, 95% CI 0.44–0.87). The median IMPACT death probability scores were lower in those who had undergone a major ECI at the initial admission than in those who had not (IMPACT score = 30, IQR 21–47 vs 36, IQR 24–58, respectively; Supplemental Table 5). Within the major ECI subgroup, median IMPACT scores for an unfavorable outcome appeared similar when comparing early versus delayed cranioplasty (IMPACT score = 48, IQR 42–73 vs 54, IQR 35–65, respectively; Supplemental Table 6). In the same subgroup, road traffic accidents were more common in the delayed cranioplasty group (19 [63%]) than in the early group (6 [32%]). There was no statistically significant difference between early and delayed cranioplasty in the patients who underwent either bifrontal craniectomy or hemicraniectomy (n = 15, aOR 0.79, 95% CI 0.21–2.7; n = 75, aOR 1.1, 95% CI 0.57–2.4, respectively). Moreover, early cranioplasty was not associated with an improved functional outcome in patients undergoing either primary (n = 62, aOR 0.62, 95% CI 0.39–1.1) or secondary (n = 52, aOR 1.2, 95% CI 0.81–1.7) DC (Fig. 3).

Lastly, in an additional subgroup analysis, there was no statistically significant difference between early and delayed cranioplasty in terms of centers preferring early over delayed cranioplasty or centers without a clear preference. In centers preferring delayed cranioplasty, early cranioplasty was associated with an improved functional outcome (aOR 2.7, 95% CI 1.1–7.1; Supplemental Fig. 4) but the subgroup sample sizes were small (early cranioplasty/total subgroup = 4/56).

Discussion

In this analysis of patients with TBI from two large observational European studies who had undergone DC and subsequent cranioplasty, we found similar functional outcomes and QOL regardless of whether the cranioplasty was performed early ($\leq$ 90 days post-DC) or was delayed (> 90 days post-DC). There was a significant positive association of early cranioplasty with an increased risk of hydrocephalus, whereas the risk of seizure did not reach significance. Different categorizations of timing did not lead to a difference in outcome in the sensitivity analyses.

A recent systematic review and meta-analysis revealed a possible positive effect of performing cranioplasty within 90 days on functional outcome. Our study could not confirm this overall treatment effect, although comparisons are difficult because the review utilized outcome measures different from ours.¹² Another systematic review demonstrated a benefit in cognitive and motor function when performing cranioplasty within 90 days after DC.¹³ Although we did not specifically evaluate cognitive and motor function, a potential difference in motor and cognitive function did not translate into a difference in functional outcome as measured with the GOSE between early and delayed cranioplasty. Furthermore, another review discussed the possible beneficial effect of early cranioplasty on functional outcome when performed as soon as brain edema had resolved.³⁴

Hydrocephalus and Seizures

Early cranioplasty was associated with a higher risk of hydrocephalus. A recent systematic review described an increased risk of hydrocephalus after cranioplasty performed within 90 days.³⁵ A large retrospective study on the timing of cranioplasty also demonstrated an increased risk of hydrocephalus with early cranioplasty.¹⁴ DC is known to alter CSF flow dynamics and cerebral blood flow dynamics, both of which change with replacement of the bone flap.^{36–39} Replacement of the bone flap can be relatively premature, limiting swelling of the brain and therefore affecting intracranial CSF dynamics. Thus, although the




FIG. 3. Subgroup analyses of primary outcome for early cranioplasty. The figure shows common odds ratios with their corresponding confidence intervals for an improvement in the ordinal GOSE score for early cranioplasty. Adjusted odds ratios were calculated using multivariable ordinal logistic regression models.

higher hydrocephalus incidence did not translate to a difference in the GOSE score or QOL, early cranioplasty must be weighed against the potentially chronic need for shunts and their complications.

Furthermore, although 15% of patients in the early group experienced seizures as compared with 9% in the delayed group, we found no statistically significant association between timing of cranioplasty and seizure occurrence. This lack of a clear association is in line with other reports.^{14,40}

Quality of Life

Studies have shown an increased QOL after cranioplasty, especially in patients harboring a large cranial defect; however, research on the effect of cranioplasty timing on QOL in TBI patients has been scant.⁴¹ Our study found no difference in the QOLIBRI score according to the timing of cranioplasty.

Polytrauma

The lack of an overall treatment effect in our study may be attributable to the averaging of heterogeneous subgroup effects. Therefore, subgroup analyses may be informative. In patients who had undergone a major ECI, early cranioplasty was associated with a favorable functional outcome at 12 months after DC (Fig. 3). Rehabilitation decisions in TBI are mainly based on injury severity, but patients who undergo a major ECI may receive relatively more intensive inpatient rehabilitation before cranioplasty or may be selected for early cranioplasty to facilitate further effective rehabilitation. Additionally, patients who recover rapidly may also be selected for early cranioplasty. Finally, many rehabilitation physicians and physical therapists are

cautious in designing rehabilitation programs for patients with a skull defect given the fear of falls and other injuries. Thus, appropriate rehabilitation in patients with delayed cranioplasty can vary, which may exert an impact on outcomes for this particular subgroup. The type, intensity, and level of rehabilitation services both pre- and postcranioplasty could significantly impact the short- and long-term trajectories of recovery and therefore have an impact on overall outcome. However, the exact explanation remains uncertain.^{42,43}

Study Strengths and Weaknesses

We report on the timing of cranioplasty after DC in the largest international multicenter cohort sample to date. We used harmonized data from 65 centers across Europe and Israel with standardized data collection. The broad inclusion criteria ensured the incorporation of all TBI severities. Considering this and the international multicenter nature of our study, we believe the findings have broad generalizability.

The primary limitation of this study is its observational design. Patient characteristics rather than the intervention may determine the outcome. Confounding by indication plays a major role in determining validity to real-world clinical practice because residual confounding may persist.^{44–47} Early cranioplasty patients exhibited lower median GCS scores, reduced pupil reactivity, and a higher incidence of midline shift, potentially indicative of more severe underlying injuries, although the differences were not statistically significant.

However, the risk of residual confounding was reduced because baseline prognoses were similar, and the discrepancy between the unadjusted and adjusted analyses was

minimal. To combat confounding, we used a multivariable regression model and PSM as sensitivity analysis. Our findings were robust since the sensitivity analysis yielded similar odds ratios (Supplemental Table 1). Also, immortal time bias may be an issue: certain patients will probably not undergo cranioplasty because of their persistently bad neurological condition and presumed very poor prognosis. This is unlikely to have led to discrepant inclusion between early and delayed cranioplasty groups because the inclusion is predominantly determined by whether brain edema has decreased sufficiently to technically allow for the procedure.

The difference in hospital length of stay may be explained by recording it only for the initial admission and may therefore be prolonged in patients undergoing cranioplasty during this initial admission. This could give a distorted image of the actual cumulative hospitalization duration. Nonetheless, the difference may also indicate potential selection bias. A prolonged hospital length of stay may influence surgical decision-making since the bony defect may become more and more apparent during daily rounds.

Unfortunately, due to limitations in the available data, we were unable to analyze bone resorption, implant loosening/dislodgment, postoperative recurrent or new hemorrhage, and (surgical site) infection rates, which are among the most typical cranioplasty complications and commonly result in cranioplasty failure.³⁵ Other studies have suggested a possible benefit of early cranioplasty to prevent autologous bone flap resorption.¹⁴ Bone resorption increases the risk of reoperation and therefore could have a biased overall effect on GOSE scores.⁴⁸ Infections are a rather common postcranioplasty complication and remain an important factor in the patient's rehabilitation period.^{14,17,18,49}

A related limitation is the frequent unavailability of precise dates of the diagnosis of hydrocephalus and seizures. These complications could have occurred before the actual cranioplasty. As described, the early cranioplasty group had hydrocephalus more often and possibly also experienced seizures more frequently. A question remains as to whether those differences resulted from baseline discrepancies or from early cranioplasty. However, from a pragmatic point of view, it simply reveals which complications may occur more often for patients who have an early cranioplasty.

Furthermore, the GOSE remains a rather crude measure for overall functional outcome and cannot be used to evaluate cognitive and motor function. This should be considered when comparing the findings of this study to other related research.

Lastly, six GOSE scores at the 12-month follow-up were missing, which could lead to mild attrition bias. Moreover, in 48 patients, 6- or 12-month follow-up assessments indicated that a cranioplasty had been performed up until those time points. However, the exact date of surgery (i.e., before or after 90 days post-DC) was missing. Therefore, the patients were excluded from analysis. By excluding the patients with missing DC-to-cranioplasty timing intervals, the results could have suffered from selection bias. However, the bias should be minimal because the missing cra-

nioplasty dates were probably random (i.e., not associated with the timing).

This study may reduce treatment variation, as it appears that delay in rebuilding the skull is likely not beneficial. However, a randomized controlled trial (RCT) with a health economic analysis must be performed to confirm our results. Specifically, the prospective nature of an RCT would permit more apposite data collection, and the randomization would be pivotal to mitigate confounding. The health economic component would test the hypothesis that earlier cranioplasty, while an inpatient, is more efficient and cost-effective but is offset by a higher rate of ventriculoperitoneal shunt placements. Still, performing RCTs in these settings is difficult because of, among other reasons, the varying treatment protocols and the perceived absence of equipoise in randomizing neurotrauma patients.⁵⁰

Conclusions

We found comparable functional and QOL outcomes between early and delayed cranioplasty in patients who undergo DC for TBI. Accordingly, neurosurgeons may wish to perform cranioplasty shortly after or during the first index admission but should remain vigilant to the increased possibility of hydrocephalus.

Acknowledgments

We would like to gratefully thank Amy J. Markowitz, JD, for her editorial support and all CENTER-TBI participants and investigators.

CENTER-TBI was supported by the European Union 7th Framework Programme for Research (grant no. 602150; A.I.R.M.), Hannelore Kohl Stiftung (Germany), and OneMind (United States). Net-QuRe was supported by the Hersenstichting Nederland (Dutch Brain Foundation, grant no. ps2014.06). Dr. Korhonen reported research grants from the Finnish Cultural Foundation, Finnish Medical Foundation, and Orion Research Foundation outside the submitted work. Dr. Yue reported grants from the Neurosurgery Research and Education Foundation and Bagan Family Foundation Research Fellowship (award no. A139203, to the University of California, San Francisco) outside the submitted work. Dr. Maas reported grants from the European Union 7th Framework Programme for Research during the conduct of the study. Dr. Peul reported grants from European Committee Grant CENTER-TBI and grants from the Netherlands Brain Foundation during the conduct of the study. Dr. Posti reported funding from the Academy of Finland (grant no. 17379) and the Maire Taponen Foundation. Dr. van Essen reported grants from the European Union 7th Framework Programme for Research or CENTER-TBI and Hersenstichting Nederland (Dutch Brain Foundation) for Net-QuRe and the Niels Stensen Fellowship during the conduct of the study. Dr. Hutchinson is supported by the National Institute for Health and Care Research (Cambridge BRC, Brain Injury Medtech Co-operative, Global Health Research Group on Acquired Brain and Spine Injury, Senior Investigator Award) and the Royal College of Surgeons of England. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Appendix

CENTER-TBI Participants and Investigators

Cecilia Åkerlund,¹ Krisztina Amrein,² Nada Andelic,³ Lasse Andreassen,⁴ Audny Anke,⁵ Anna Antoni,⁶ Gérard Audibert,⁷ Philippe Azouvi,⁸ Maria Luisa Azzolini,⁹ Ronald Bartels,¹⁰

- Pál Barzó,¹¹ Romuald Beauvais,¹² Ronny Beer,¹³ Bo-Michael Bellander,¹⁴ Antonio Belli,¹⁵ Habib Benali,¹⁶ Maurizio Berardino,¹⁷ Luigi Beretta,¹⁸ Morten Blaabjerg,¹⁹ Peter Bragge,¹⁹ Alexandra Brazinova,²⁰ Vibeke Brinck,²¹ Joanne Brooker,²² Camilla Brorsson,²³ Andras Buki,²⁴ Monika Bullinger,²⁵ Manuel Cabeleira,²⁶ Alessio Caccioppola,²⁷ Emiliana Calappi,²⁷ Maria Rosa Calvi,⁹ Peter Cameron,²⁸ Guillermo Carbayo Lozano,²⁹ Marco Carbonara,²⁷ Simona Cavallo,¹⁷ Giorgio Chevallard,³⁰ Arturo Chieragato,³⁰ Giuseppe Citerio,^{31,32} Hans Clusmann,³³ Mark Coburn,³⁴ Jonathan Coles,³⁵ Jamie D. Cooper,³⁶ Marta Correia,³⁷ Amra Čović,³⁸ Nicola Curry,³⁹ Endre Czeiter,²⁴ Marek Czosnyka,²⁶ Claire Dahyot-Fizelier,⁴⁰ Paul Dark,⁴¹ Helen Dawes,⁴² Véronique De Keyser,⁴³ Vincent Degos,¹⁶ Francesco Della Corte,⁴⁴ Hugo den Boogert,¹⁰ Bart Depreitere,⁴⁵ Dula Dilvesi,⁴⁶ Abhishek Dixit,⁴⁷ Emma Donoghue,²² Jens Dreier,⁴⁸ Guy-Loup Dulière,⁴⁹ Ari Ercole,⁴⁷ Patrick Esser,⁴² Erzsébet Ezer,⁵⁰ Martin Fabricius,⁵¹ Valery L. Feigin,⁵² Kelly Foks,⁵³ Shirin Frisvold,⁵⁴ Alex Furmanov,⁵⁵ Pablo Gagliardo,⁵⁶ Damien Galanaud,¹⁶ Dashiell Gantner,²⁸ Guoyi Gao,⁵⁷ Pradeep George,⁵⁸ Alexandre Ghuysen,⁵⁹ Lelde Giga,⁶⁰ Ben Glocker,⁶¹ Jagoš Golubovic,⁴⁶ Pedro A. Gomez,⁶² Johannes Gratz,⁶³ Benjamin Gravesteijn,⁶⁴ Francesca Grossi,⁴⁴ Russell L. Gruen,⁶⁵ Deepak Gupta,⁶⁶ Juanita A. Haagsma,⁶⁴ Iain Haitsma,⁶⁷ Raimund Helbok,¹³ Eirik Helseth,⁶⁸ Lindsay Horton,⁶⁹ Jilke Huijben,⁶⁴ Peter J. Hutchinson,⁷⁰ Bram Jacobs,⁷¹ Stefan Jankowski,⁷² Mike Jarrett,²¹ Ji-yao Jiang,⁵⁸ Faye Johnson,⁷³ Kelly Jones,⁵² Mladen Karan,⁴⁶ Angelos G. Kolias,⁷⁰ Erwin Kompanje,⁷⁴ Daniel Kondziella,⁵¹ Evgenios Kornaropoulos,⁴⁷ Lars-Owe Koskinen,⁷⁵ Noémi Kovács,⁷⁶ Ana Kowark,⁷⁷ Alfonso Lagares,⁶² Linda Lanyon,⁵⁸ Steven Laureys,⁷⁸ Fiona Lecky,^{79,80} Didier Ledoux,⁷⁸ Rolf Lefering,⁸¹ Valerie Legrand,⁸² Aurelie Lejeune,⁸³ Leon Levi,⁸⁴ Roger Lightfoot,⁸⁵ Hester Lingsma,⁶⁴ Andrew I. R. Maas,⁴³ Ana M. Castaño-León,⁶² Marc Maegele,⁸⁶ Marek Majdan,²⁰ Alex Manara,⁸⁷ Geoffrey Manley,⁸⁸ Costanza Martino,⁸⁹ Hugues Maréchal,⁴⁹ Julia Mattern,⁹⁰ Catherine McMahon,⁹¹ Béla Meleg,⁹² David Menon,⁴⁷ Tomas Menovsky,⁴³ Ana Mikolic,⁶⁴ Benoît Misset,⁷⁸ Visakh Muralledharan,⁵⁸ Lynnette Murray,²⁸ Ancuta Negru,⁹³ David Nelson,¹ Virginia Newcombe,⁴⁷ Daan Nieboer,⁶⁴ József Nyírádi,² Otesile Olubukola,⁷⁹ Matej Oresic,⁹⁴ Fabrizio Ortolano,²⁷ Aarno Palotie,^{95–97} Paul M. Parizel,⁹⁸ Jean-François Payen,⁹⁹ Natascha Perera,¹² Vincent Perlbarg,¹⁶ Paolo Persona,¹⁰⁰ Wilco Peul,¹⁰¹ Anna Piippo-Karjalainen,¹⁰² Matti Pirinen,⁹⁵ Dana Pisica,⁶⁴ Horia Ples,⁹³ Suzanne Polinder,⁶⁴ Inigo Pomposo,²⁹ Jussi P. Posti,¹⁰³ Louis Puybasset,¹⁰⁴ Andreea Radoi,¹⁰⁵ Arminas Ragauskas,¹⁰⁶ Rahul Raj,¹⁰² Malinka Rambadagalla,¹⁰⁷ Isabel Retel Helmrich,⁶⁴ Jonathan Rhodes,¹⁰⁸ Sylvia Richardson,¹⁰⁹ Sophie Richter,⁴⁷ Samuli Ripatti,⁹⁵ Saulius Rocka,¹⁰⁶ Cecilie Roe,¹¹⁰ Olav Roise,^{111,112} Jonathan Rosand,¹¹³ Jeffrey V. Rosenfeld,¹¹⁴ Christina Rosenlund,¹¹⁵ Guy Rosenthal,⁵⁵ Rolf Rossaint,⁷⁷ Sandra Rossi,¹⁰⁰ Daniel Rueckert,⁶¹ Martin Rusnák,¹¹⁶ Juan Sahuquillo,¹⁰⁵ Oliver Sakowitz,^{90,117} Renan Sanchez-Porras,¹¹⁷ Janos Sandor,¹¹⁸ Nadine Schäfer,⁸¹ Silke Schmidt,¹¹⁹ Herbert Schoechl,¹²⁰ Guus Schoonman,¹²¹ Rico Frederik Schou,¹²² Elisabeth Schwendenwein,⁶ Charlie Sewalt,⁶⁴ Ranjit D. Singh,¹⁰¹ Toril Skandsen,^{123,124} Peter Smielewski,²⁶ Abayomi Sorinola,¹²⁵ Emmanuel Stamatakis,⁴⁷ Simon Stanworth,³⁹ Robert Stevens,¹²⁶ William Stewart,¹²⁷ Ewout W. Steyerberg,^{64,128} Nino Stocchetti,¹²⁹ Nina Sundström,¹³⁰ Riikka Takala,¹³¹ Viktória Tamás,¹²⁵ Tomas Tamosiutis,¹³² Mark Steven Taylor,²⁰ Aureore Thibaut,⁷⁸ Braden Te Ao,⁵² Olli Tenovuori,¹⁰³ Alice Theadom,⁵² Matt Thomas,⁸⁷ Dick Tibboel,¹³³ Marjolein Timmers,⁷⁴ Christos Toliaas,¹³⁴ Tony Trapani,²⁸ Cristina Maria Tudora,⁹³ Andreas Unterberg,⁹⁰ Peter Vajkoczy,¹³⁵ Shirley Vallance,²⁸ Egils Valeinis,⁶⁰ Zoltán Vámos,⁵⁰ Mathieu van der Jagt,¹³⁶ Gregory Van der Steen,⁴³ Joukje van der Naalt,⁷¹ Jeroen T. J. M. van Dijk,¹⁰¹ Inge A. M. van Erp,¹⁰¹ Thomas A. van Essen,¹⁰¹ Wim Van Hecke,¹³⁷ Caroline van Heugten,¹³⁸ Dominique Van Praag,¹³⁹ Ernest van Veen,⁶⁴ Thijs Van de Vyvere,¹³⁷ Roel P. J. van Wijk,¹⁰¹ Alessia Vargiolu,³² Emmanuel Vega,⁸³ Kimberley Velt,⁶⁴ Jan Verheyden,¹³⁷ Paul M. Vespa,¹⁴⁰ Anne Vik,^{123,141} Rimantas Vilcinis,¹³² Victor Volovici,⁶⁷ Nicole von Steinbüchel,³⁸ Daphne Voormolen,⁶⁴ Petar Vulekovic,⁴⁶ Kevin K. W. Wang,¹⁴² Daniel Whitehouse,⁴⁷ Eveline Wiegers,⁶⁴ Guy Williams,⁴⁷ Lindsay Wilson,⁶⁹ Stefan Winzeck,⁴⁷ Stefan Wolf,¹⁴³ Zhihui Yang,¹¹³ Peter Ylén,¹⁴⁴ Alexander Younsi,⁹⁰ Frederick A. Zeiler,^{47,145} Veronika Zelinkova,²⁰ Agate Ziverte,⁶⁰ and Tommaso Zoerle.²⁷
- ¹Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden; ²János Szentágothai Research Centre, University of Pécs, Hungary; ³Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Norway; ⁴Department of Neurosurgery, University Hospital Northern Norway, Tromsø, Norway; ⁵Department of Physical Medicine and Rehabilitation, University Hospital Northern Norway, Tromsø, Norway; ⁶Trauma Surgery, Medical University Vienna, Austria; ⁷Department of Anesthesiology and Intensive Care, University Hospital Nancy, France; ⁸Raymond Poincaré Hospital, Assistance Publique–Hôpitaux de Paris, France; ⁹Department of Anesthesiology and Intensive Care, San Raffaele University Hospital, Milan, Italy; ¹⁰Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands; ¹¹Department of Neurosurgery, University of Szeged, Hungary; ¹²International Projects Management, ARTTIC, Munchen, Germany; ¹³Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Austria; ¹⁴Department of Neurosurgery and Anesthesia and Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden; ¹⁵NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, United Kingdom; ¹⁶Anesthésie-Réanimation, Assistance Publique–Hôpitaux de Paris, France; ¹⁷Department of Anesthesia and ICU, AOU Città della Salute e della Scienza di Torino–Orthopedic and Trauma Center, Torino, Italy; ¹⁸Department of Neurology, Odense University Hospital, Odense, Denmark; ¹⁹BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Melbourne, Victoria, Australia; ²⁰Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia; ²¹Quesgen Systems Inc., Burlingame, California; ²²Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; ²³Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden; ²⁴Department of Neurosurgery, Medical School, University of Pécs, Hungary and Neurotrauma Research Group, János Szentágothai Research Centre, University of Pécs, Hungary; ²⁵Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; ²⁶Brain Physics Lab, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; ²⁷Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; ²⁸ANZIC Research Centre, Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia; ²⁹Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain; ³⁰NeuroIntensive Care, Niguarda Hospital, Milan, Italy; ³¹School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy; ³²NeuroIntensive Care Unit, Department of Neuroscience, IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy; ³³Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, Germany; ³⁴Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Germany; ³⁵Department of Anesthesia and Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom; ³⁶School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia; ³⁷Radiology/MRI Department, MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom; ³⁸Institute of

- Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Germany; ³⁹Oxford University Hospitals NHS Trust, Oxford, United Kingdom; ⁴⁰Intensive Care Unit, CHU Poitiers, France; ⁴¹University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom; ⁴²Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, United Kingdom; ⁴³Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium; ⁴⁴Department of Anesthesia and Intensive Care, Maggiore Della Carità Hospital, Novara, Italy; ⁴⁵Department of Neurosurgery, University Hospitals Leuven, Belgium; ⁴⁶Department of Neurosurgery, Clinical Centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia; ⁴⁷Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; ⁴⁸Center for Stroke Research Berlin, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; ⁴⁹Intensive Care Unit, CHR Citadelle, Liège, Belgium; ⁵⁰Department of Anaesthesiology and Intensive Therapy, University of Pécs, Hungary; ⁵¹Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark; ⁵²National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand; ⁵³Department of Neurology, Erasmus MC, Rotterdam, The Netherlands; ⁵⁴Department of Anesthesiology and Intensive Care, University Hospital Northern Norway, Tromsø, Norway; ⁵⁵Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; ⁵⁶Fundación Instituto Valenciano de Neurorehabilitación (FIVAN), Valencia, Spain; ⁵⁷Department of Neurosurgery, Shanghai Renji Hospital, Shanghai Jiaotong University/School of Medicine, Shanghai, China; ⁵⁸Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, Stockholm, Sweden; ⁵⁹Emergency Department, CHU, Liège, Belgium; ⁶⁰Neurosurgery Clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia; ⁶¹Department of Computing, Imperial College London, United Kingdom; ⁶²Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain; ⁶³Department of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Austria; ⁶⁴Department of Public Health, Erasmus Medical Center–University Medical Center, Rotterdam, The Netherlands; ⁶⁵College of Health and Medicine, Australian National University, Canberra, Australia; ⁶⁶Department of Neurosurgery, Neurosciences Centre & JPN Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India; ⁶⁷Department of Neurosurgery, Erasmus MC, Rotterdam, The Netherlands; ⁶⁸Department of Neurosurgery, Oslo University Hospital, Oslo, Norway; ⁶⁹Division of Psychology, University of Stirling, United Kingdom; ⁷⁰Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, United Kingdom; ⁷¹Department of Neurology, University of Groningen, University Medical Center Groningen, The Netherlands; ⁷²Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; ⁷³Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, United Kingdom; ⁷⁴Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; ⁷⁵Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden; ⁷⁶Hungarian Brain Research Program, University of Pécs, Hungary; ⁷⁷Department of Anaesthesiology, University Hospital of Aachen, Germany; ⁷⁸Cyclotron Research Center, University of Liège, Belgium; ⁷⁹Centre for Urgent and Emergency Care Research (CURE), Health Services Research Section, School of Health and Related Research (SchARR), University of Sheffield, United Kingdom; ⁸⁰Emergency Department, Salford Royal Hospital, Salford, United Kingdom; ⁸¹Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany; ⁸²VP Global Project Management CNS, ICON, Paris, France; ⁸³Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France; ⁸⁴Department of Neurosurgery, Rambam Medical Center, Haifa, Israel; ⁸⁵Department of Anesthesiology & Intensive Care, University Hospitals Southampton NHS Trust, Southampton, United Kingdom; ⁸⁶Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany; ⁸⁷Intensive Care Unit, Southmead Hospital, Bristol, United Kingdom; ⁸⁸Department of Neurological Surgery, University of California, San Francisco, California; ⁸⁹Department of Anesthesia and Intensive Care, M. Bufalini Hospital, Cesena, Italy; ⁹⁰Department of Neurosurgery, University Hospital Heidelberg, Germany; ⁹¹Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; ⁹²Department of Medical Genetics, University of Pécs, Hungary; ⁹³Department of Neurosurgery, Emergency County Hospital Timisoara, Romania; ⁹⁴School of Medical Sciences, Örebro University, Örebro, Sweden; ⁹⁵Institute for Molecular Medicine Finland, University of Helsinki, Finland; ⁹⁶Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; ⁹⁷Program in Medical and Population Genetics, The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts; ⁹⁸Department of Radiology, University of Antwerp, Edegem, Belgium; ⁹⁹Department of Anesthesiology and Intensive Care, University Hospital of Grenoble, France; ¹⁰⁰Department of Anesthesia and Intensive Care, Azienda Ospedaliera Università di Padova, Italy; ¹⁰¹Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and Department of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands; ¹⁰²Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland; ¹⁰³Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury Centre, Turku University Hospital and University of Turku, Finland; ¹⁰⁴Department of Anesthesiology and Critical Care, Pitié-Salpêtrière Teaching Hospital, Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France; ¹⁰⁵Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research Institute, Barcelona, Spain; ¹⁰⁶Department of Neurosurgery, Kaunas University of Technology and Vilnius University, Vilnius, Lithuania; ¹⁰⁷Department of Neurosurgery, Rezekne Hospital, Latvia; ¹⁰⁸Department of Anaesthesia, Critical Care and Pain Medicine, NHS Lothian & University of Edinburgh, United Kingdom; ¹⁰⁹MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, United Kingdom; Departments of ¹¹⁰Physical Medicine and Rehabilitation and ¹¹¹Orthopedics, Oslo University Hospital and University of Oslo, Norway; ¹¹²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway; ¹¹³Broad Institute, Cambridge; Harvard Medical School, Boston; Massachusetts General Hospital, Boston, Massachusetts; ¹¹⁴National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia; ¹¹⁵Department of Neurosurgery, Odense University Hospital, Odense, Denmark; ¹¹⁶International Neurotrauma Research Organisation, Vienna, Austria; ¹¹⁷Klinik für Neurochirurgie, Klinikum Ludwigsburg, Germany; ¹¹⁸Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Hungary; ¹¹⁹Department of Health and Prevention, University Greifswald, Germany; ¹²⁰Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria; ¹²¹Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands; ¹²²Department of Neuroanesthesia and

Neurointensive Care, Odense University Hospital, Odense, Denmark; ¹²³Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, NTNU, Trondheim, Norway; ¹²⁴Department of Physical Medicine and Rehabilitation, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; ¹²⁵Department of Neurosurgery, University of Pécs, Hungary; ¹²⁶Division of Neuroscience Critical Care, John Hopkins University School of Medicine, Baltimore, Maryland; ¹²⁷Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, United Kingdom; ¹²⁸Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; ¹²⁹Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; ¹³⁰Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden; ¹³¹Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Finland; ¹³²Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania; ¹³³Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands; ¹³⁴Department of Neurosurgery, King's College London, United Kingdom; ¹³⁵Neurologie, Neurochirurgie und Psychiatrie, Charité–Universitätsmedizin Berlin, Germany; ¹³⁶Department of Intensive Care Adults, Erasmus MC–University Medical Center Rotterdam, The Netherlands; ¹³⁷icoMetrix NV, Leuven, Belgium; ¹³⁸Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, United Kingdom; ¹³⁹Psychology Department, Antwerp University Hospital, Edegem, Belgium; ¹⁴⁰Neurocritical Care, University of California, Los Angeles, California; ¹⁴¹Department of Neurosurgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; ¹⁴²Department of Emergency Medicine, University of Florida, Gainesville, Florida; ¹⁴³Department of Neurosurgery, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; ¹⁴⁴VTT Technical Research Centre, Tampere, Finland; and ¹⁴⁵Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

References

1. Traumatisch hersenletsel (THL) zorgstandaard. Zorginstituut Nederland. Accessed February 15, 2024. <https://www.zorginzicht.nl/kwaliteitsinstrumenten/traumatisch-hersenletsel-thl-zorgstandaard>
2. Brazinova A, Rehorcikova V, Taylor MS, et al. Epidemiology of traumatic brain injury in Europe: a living systematic review. *J Neurotrauma*. 2021;38(10):1411-1440.
3. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019;18(1):56-87.
4. Hutchinson PJ, Adams H, Mohan M, et al. Decompressive craniectomy versus craniotomy for acute subdural hematoma. *N Engl J Med*. 2023;388(24):2219-2229.
5. Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. *N Engl J Med*. 2011;364(16):1493-1502.
6. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. *N Engl J Med*. 2016;375(12):1119-1130.
7. Kunze E, Meixensberger J, Janka M, Sörensen N, Roosen K. Decompressive craniectomy in patients with uncontrollable intracranial hypertension. *Acta Neurochir Suppl*. 1998;71:16-18.
8. Schneider GH, Bardt T, Lanksch WR, Unterberg A. Decompressive craniectomy following traumatic brain injury: ICP, CPP and neurological outcome. *Acta Neurochir Suppl*. 2002;81:77-79.
9. Aarabi B, Hesdorffer DC, Ahn ES, Aresco C, Scalea TM, Eisenberg HM. Outcome following decompressive craniectomy for malignant swelling due to severe head injury. *J Neurosurg*. 2006;104(4):469-479.
10. Kolias AG, Adams H, Timofeev IS, et al. Evaluation of outcomes among patients with traumatic intracranial hypertension treated with decompressive craniectomy vs standard medical care at 24 months: a secondary analysis of the RESCUEicp randomized clinical trial. *JAMA Neurol*. 2022;79(7):664-671.
11. Cnossen MC, Huijben JA, van der Jagt M, et al. Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study. *Crit Care*. 2017;21(1):233.
12. Malcolm JG, Rindler RS, Chu JK, et al. Early Cranioplasty is associated with greater neurological improvement: a systematic review and meta-analysis. *Neurosurgery*. 2018;82(3):278-288.
13. De Cola MC, Corallo F, Pria D, Lo Buono V, Calabrò RS. Timing for cranioplasty to improve neurological outcome: a systematic review. *Brain Behav*. 2018;8(11):e01106.
14. Morton RP, Abecassis JJ, Hanson JF, et al. Timing of cranioplasty: a 10.75-year single-center analysis of 754 patients. *J Neurosurg*. 2018;128(6):1648-1652.
15. Bender A, Heulin S, Röhrer S, et al. Early cranioplasty may improve outcome in neurological patients with decompressive craniectomy. *Brain Inj*. 2013;27(9):1073-1079.
16. Chibbaro S, Di Rocco F, Mirone G, et al. Decompressive craniectomy and early cranioplasty for the management of severe head injury: a prospective multicenter study on 147 patients. *World Neurosurg*. 2011;75(3-4):558-562.
17. De Bonis P, Frassanito P, Mangiola A, Nucci CG, Anile C, Pompucci A. Cranial repair: how complicated is filling a "hole"? *J Neurotrauma*. 2012;29(6):1071-1076.
18. Piedra MP, Nemecek AN, Ragel BT. Timing of cranioplasty after decompressive craniectomy for trauma. *Surg Neurol Int*. 2014;5:25.
19. Mee H, Anwar F, Timofeev I, et al. Cranioplasty: a multidisciplinary approach. *Front Surg*. 2022;9:864385.
20. Li A, Azad TD, Veeravagu A, et al. Cranioplasty complications and costs: a national population-level analysis using the MarketScan longitudinal database. *World Neurosurg*. 2017;102:209-220.
21. Liu L, Lu ST, Liu AH, et al. Comparison of complications in cranioplasty with various materials: a systematic review and meta-analysis. *Br J Neurosurg*. 2020;34(4):388-396.
22. Ashayeri K, M Jackson E, Huang J, Brem H, Gordon CR. Syndrome of the trephined: a systematic review. *Neurosurgery*. 2016;79(4):525-534.
23. Iaccarino C, Kolias A, Adelson PD, et al. Consensus statement from the international consensus meeting on post-traumatic cranioplasty. *Acta Neurochir (Wien)*. 2021;163(2):423-440.
24. Maas AI, Menon DK, Steyerberg EW, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. *Neurosurgery*. 2015;76(1):67-80.
25. Approved proposals. CENTER-TBI. Accessed February 15, 2024. <https://www.center-tbi.eu/data/approved-proposals>
26. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg*. 2014;12(12):1500-1524.
27. Chang V, Hartzfeld P, Langlois M, Mahmood A, Seyfried D.

- Outcomes of cranial repair after craniectomy. *J Neurosurg*. 2010;112(5):1120-1124.
28. Song J, Liu M, Mo X, Du H, Huang H, Xu GZ. Beneficial impact of early cranioplasty in patients with decompressive craniectomy: evidence from transcranial Doppler ultrasonography. *Acta Neurochir (Wien)*. 2014;156(1):193-198.
 29. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. *J Neurotrauma*. 1998;15(8):573-585.
 30. von Steinbüchel N, Petersen C, Bullinger M. Assessment of health-related quality of life in persons after traumatic brain injury—development of the Qolibri, a specific measure. *Acta Neurochir Suppl*. 2005;93:43-49.
 31. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. *PLoS Med*. 2008;5(8):e165.
 32. Roozenbeek B, Lingsma HF, Lecky FE, et al. Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models. *Crit Care Med*. 2012;40(5):1609-1617.
 33. Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. *J Neurotrauma*. 2007;24(2):329-337.
 34. Iaccarino C, Kolias AG, Roumy LG, Fountas K, Adeleye AO. Cranioplasty following decompressive craniectomy. Review. *Front Neurol*. 2020;10(1357):1357.
 35. Malcolm JG, Rindler RS, Chu JK, Grossberg JA, Pradilla G, Ahmad FU. Complications following cranioplasty and relationship to timing: a systematic review and meta-analysis. *J Clin Neurosci*. 2016;33:39-51.
 36. Won YD, Yoo DS, Kim KT, et al. Cranioplasty effect on the cerebral hemodynamics and cardiac function. *Acta Neurochir Suppl (Wien)*. 2008;102:15-20.
 37. Halani SH, Chu JK, Malcolm JG, et al. Effects of cranioplasty on cerebral blood flow following decompressive craniectomy: a systematic review of the literature. *Neurosurgery*. 2017;81(2):204-216.
 38. Stiver SI, Wintermark M, Manley GT. Motor trephine syndrome: a mechanistic hypothesis. *Acta Neurochir Suppl (Wien)*. 2008;102:273-277.
 39. Czosnyka M, Copeman J, Czosnyka Z, McConnell R, Dickinson C, Pickard JD. Post-traumatic hydrocephalus: influence of craniectomy on the CSF circulation. *J Neurol Neurosurg Psychiatry*. 2000;68(2):246-248.
 40. Aloraidi A, Alkhaibary A, Alharbi A, et al. Effect of cranioplasty timing on the functional neurological outcome and postoperative complications. *Surg Neurol Int*. 2021;12:264.
 41. Worm PV, Finger G, Ludwig do Nascimento T, Rynkowski CB, Collares MVM. The impact of cranioplasty on the patients' quality of life. *J Craniomaxillofac Surg*. 2019;47(5):715-719.
 42. Posti JP, Yli-Olli M, Heiskanen L, et al. Cranioplasty after severe traumatic brain injury: effects of trauma and patient recovery on cranioplasty outcome. *Front Neurol*. 2018;9:223.
 43. Meier U, Gräwe A, König A. The importance of major extracranial injuries by the decompressive craniectomy in severe head injuries. *Acta Neurochir Suppl*. 2005;95:55-57.
 44. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidemiol Drug Saf*. 2010;19(6):537-554.
 45. Cnossen MC, van Essen TA, Ceyisakar IE, et al. Adjusting for confounding by indication in observational studies: a case study in traumatic brain injury. *Clin Epidemiol*. 2018;10:841-852.
 46. van Essen TA, Menon DK, Lingsma HF. Unmeasured confounding in observational studies of management of cerebellar intracranial hemorrhage. *JAMA*. 2020;323(7):665-666.
 47. van Essen TA, Lingsma HF, Pisică D, et al. Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study. *Lancet Neurol*. 2022;21(7):620-631.
 48. Rashidi A, Sandalcioğlu IE, Luchtmann M. Aseptic bone-flap resorption after cranioplasty—incidence and risk factors. *PLoS One*. 2020;15(1):e0228009.
 49. Oh JS, Lee KS, Shim JJ, Yoon SM, Doh JW, Bae HG. Which one is better to reduce the infection rate, early or late cranioplasty? *J Korean Neurosurg Soc*. 2016;59(5):492-497.
 50. Maas AIR, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. *Neurotherapeutics*. 2010;7(1):115-126.

Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions

Conception and design: Vreeburg, Korhonen, Kolias, Hutchinson, de Ruiter, Maas, Peul, van Dijk, Posti, van Essen. Acquisition of data: Vreeburg, Singh, van Erp, Depreitere, Manley, Maas, van Dijk, van Essen. Analysis and interpretation of data: Vreeburg, Singh, van Erp, Korhonen, Yue, Hutchinson, Steyerberg, Maas, van Dijk, Posti, van Essen. Drafting the article: Vreeburg, Singh, Korhonen, Yue, Hutchinson, Peul, Posti, van Essen. Critically revising the article: Vreeburg, Singh, Korhonen, Yue, Mee, Timofeev, Kolias, Helmy, Depreitere, Moojen, Younsi, Hutchinson, Manley, Steyerberg, de Ruiter, Maas, Peul, van Dijk, den Boogert, Posti, van Essen. Reviewed submitted version of manuscript: Singh, van Erp, Korhonen, Yue, Mee, Timofeev, Kolias, Moojen, Younsi, Hutchinson, Manley, Steyerberg, de Ruiter, Maas, Peul, van Dijk, den Boogert, Posti, van Essen. Approved the final version of the manuscript on behalf of all authors: Vreeburg. Statistical analysis: Vreeburg, Steyerberg, van Essen. Administrative/technical/material support: Manley, van Essen. Study supervision: Moojen, Hutchinson, Manley, Peul, van Essen.

Supplemental Information

Online-Only Content

Supplemental material is available with the online version of the article.

Supplemental Tables and Figures. <https://thejns.org/doi/suppl/10.3171/2024.1.JNS232172>.

Previous Presentations

The abstract and figures were presented as an oral presentation at the European Association of Neurosurgical Societies (EANS) Annual Congress held in Barcelona, Spain, on September 24–28, 2023, and during the EANS cranioplasty webinar “Cranioplasty 2.0—Current Standards and Trends” on November 29, 2023.

Correspondence

Rick J. G. Vreeburg: University Neurosurgical Center Holland, Leiden University Medical Center, Haaglanden Medical Center and Haga Teaching Hospital, Leiden and The Hague, The Netherlands. r.j.g.vreeburg@lumc.nl.